Literature DB >> 35062259

Comparison of Plaque Size, Thermal Stability, and Replication Rate among SARS-CoV-2 Variants of Concern.

Gi Uk Jeong1, Gun Young Yoon1, Hyun Woo Moon1, Wooseong Lee1, Insu Hwang1, Haesoo Kim1, Kyun-Do Kim1, Chonsaeng Kim1, Dae-Gyun Ahn1, Bum-Tae Kim1, Seong-Jun Kim1, Young-Chan Kwon1.   

Abstract

SARS-CoV-2, like other RNA viruses, has a propensity for genetic evolution owing to the low fidelity of its viral polymerase. Several recent reports have described a series of novel SARS-CoV-2 variants. Some of these have been identified as variants of concern (VOCs), including alpha (B.1.1.7, Clade GRY), beta (B.1.351, Clade GH), gamma (P.1, Clade GR), and delta (B.1.617.2, Clade G). VOCs are likely to have some effect on transmissibility, antibody evasion, and changes in therapeutic or vaccine effectiveness. However, the physiological and virological understanding of these variants remains poor. We demonstrated that these four VOCs exhibited differences in plaque size, thermal stability at physiological temperature, and replication rates. The mean plaque size of beta was the largest, followed by those of gamma, delta, and alpha. Thermal stability, evaluated by measuring infectivity and half-life after prolonged incubation at physiological temperature, was correlated with plaque size in all variants except alpha. However, despite its relatively high thermal stability, alpha's small plaque size resulted in lower replication rates and fewer progeny viruses. Our findings may inform further virological studies of SARS-CoV-2 variant characteristics, VOCs, and variants of interest. These studies are important for the effective management of the COVID-19 pandemic.

Entities:  

Keywords:  SARS-CoV-2; replication rate; thermal stability; variants of concern

Mesh:

Year:  2021        PMID: 35062259      PMCID: PMC8781966          DOI: 10.3390/v14010055

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


1. Introduction

Several novel variants of SARS-CoV-2 have been identified since the COVID-19 pandemic began in December 2019. Although the expected mutation rate for SARS-CoV-2 is estimated to be approximately 2.4 × 10−3 per site per year [1], significantly more mutations and deletions across thousands of variants, all of which may alter their pathogenic potential, have already been reported [2]. The World Health Organization identifies novel SARS-CoV-2 variants of concern (VOCs) based on their potential impact on public health, according to evidence of enhanced transmissibility, increased severity, reduced antibody neutralization arising from former infection or vaccination, detection evasion ability, or decreased treatment or vaccine efficacy [3]. There are currently only four circulating SARS-CoV-2 VOCs: alpha (B.1.1.7, clade GRY), beta (B.1.351, clade GH), gamma (P.1, clade GR), and delta (B.1.617.2, clade G). They share D614G mutation, conferring increased infectivity, likely due to changes affecting the receptor binding and fusion [4,5,6,7]. N501Y mutation is also shared by alpha, beta, and gamma, increasing their receptor-binding affinity and subsequent cellular entry [8]. However, the combination of mutations could result in greater conformational changes and distinctive modifications [9]. For example, VOCs exhibit differential receptor-binding affinity. Alpha requires the most force to be detached from the receptor, followed by beta/gamma and delta [10].

2. Materials and Methods

2.1. Cell Lines and Viruses

Vero E6 cells (ATCC, CCL-1586) were maintained in Eagle’s minimal essential medium (EMEM; WELGENE) supplemented with 10% fetal bovine serum (FBS; Gibco, Carlsbad, CA, USA) and 100 U/mL penicillin-streptomycin (P/S; Gibco). Three micrograms of pCMV3-TMPRSS2-HA plasmid DNA (Cat# 40143-R001, Sino Biological, Beijing, China) was transfected into Vero E6 cells in a 6-well plate using Lipofectamine LTX and PLUS reagent (Cat# 15338-100, Invitrogen, Carlsbad, CA, USA) as per the protocol. After maintaining the cells in non-selective medium for 2 days, the cells were placed in selective medium containing 500 μg/mL of Hygromycin B (Cat# ant-hg-1, Invivogen) until un-transfected control cells completely died. The survived cells were further maintained in the medium containing 200 μg/mL of Hygromycin B and used for the plaque assay as Vero E6-TMPRSS2 cells. SARS-CoV-2 variants (NCCP number: 43,381 (alpha), 43,382 (beta), 43,388 (gamma), and 43,390 (delta)) were obtained from the National Culture Collection of Pathogens of South Korea (NCCP). The S protein mutations of all four VOCs used in this study were confirmed by RNA-seq (Alpha: N501Y, A570D, D614G, P681H, T716I, S982A, D1118H; Beta: L18F, D80A, D215G, K417N, E484K, N501Y, D614G, A701V; Gamma: E484K, D614G, V1176F; Delta: T19R, G142D, E156G, Δ157-158, L452R, T478K, D614G, P681R). All experiments involving infectious SARS-CoV-2 variants were performed in a biosafety level 3 (BSL-3) containment laboratory at the Korean Research Institute for Chemical Technology (KRICT, Daejeon, South Korea).

2.2. Viral Titer Determination

Plaque- and focus-forming assays were performed as previously reported with some modifications [11]. In brief, for the plaque assay, the virus was serially diluted in EMEM supplemented with 2% FBS. The cell culture medium was removed from Vero E6 or Vero E6-TMPRSS2 cells (1 × 105 per 24-well) 1 day prior to the assay, before the inoculum was transferred onto triplicate cell monolayers. These cells were incubated at 37 °C for 1 h, and the inoculum was discarded before the infected cells were overlaid with 1.8% carboxymethyl cellulose in MEM. Samples were incubated at 37 °C for 3 days (Vero E6-TMPRSS2) or 4 days (Vero E6) before they were fixed and stained using 0.05% crystal violet in 1% formaldehyde. Plaque counts and size evaluations were completed using an ImmunoSpot analyzer (C.T.L). For the focus-forming assay, Vero E6 cells (2 × 104 per 96-well) were infected with diluted inoculum for 1 h and then placed in fresh medium for an additional 8 h, after which they were washed and fixed. Cells were then stained with the N-specific antibody (Cat# 40143-R001, Sino Biological) and secondary horseradish peroxidase-conjugated goat anti-rabbit IgG (Cat# 170-6515, Bio-Rad, Hercules, CA, USA). The signal was then developed using an insoluble TMB substrate (Promega, Madison, WI, USA), and the number of infected cells was counted using an ImmunoSpot analyzer. Intra- and extracellular viral RNA was quantified using quantitative RT-PCR (QuantStudio 3, Applied Biosystems, Foster City, CA, USA), which was completed using the one-step Prime script III qRT-PCR mix (Takara). Viral RNA was detected using a 2019-nCoV-N1 probe (Cat#10006770, Integrated DNA Technologies, Coralville, IA, USA).

2.3. Statistical Analysis

Mean values for the plaque size and half-life assays were compared using one-way ANOVA in GraphPad Prism 8.0 software (GraphPad Software, San Diego, CA, USA). Statistical significance was set at p < 0.05.

3. Results

Here, we noted that each of these variants presented with different plaque sizes in Vero E6 cells (Figure 1A). The mean plaque size of beta was largest, followed by those of gamma, delta, and alpha (Figure 1B). A similar result of different plaque sizes was obtained in Vero E6-TMPRSS2 cells (Figure 1C,D). While there are numerous determinants of plaque size, we hypothesized that changes in the receptor-binding affinity, thermal stability, and replication rate of these viruses were likely factors. Based on the previously reported receptor-binding affinity data described above, we examined the thermal stability and replication rate of each of these VOCs. If a variant experiences increased stability at physiological temperatures and produces more progeny viruses, more infectious viral particles are yielded, infecting more cells and increasing the plaque size. Given this, we first assessed the thermal stability of these variants in culture media incubated at different temperatures over an 8-h period. Their infectivity was then measured using a focus-forming assay. Owing to the short incubation time following viral infection, this assay allowed for more precise assessments of virion infectivity, as it is less affected by other factors associated with viral replication.
Figure 1

Comparison of the plaque size of four SARS-CoV-2 variants. (A) Representative images of the plaque forming assay for each variant of concern in Vero E6 cells. (B) The mean plaque size (1 × 10−3 mm2) of each variant. (C) The images of the plaque forming assay for each variant of concern in Vero E6-TMPRSS2 cells. (D) The mean plaque size of each variant. All error bars indicate the standard errors of the mean. Mean values for the plaque size were compared using one-way ANOVA in GraphPad Prism 8.0 software. Statistical significance was set at p < 0.05. (****, p < 0.0001).

Of the four VOCs, the beta variant was the most stable at 4, 24, and 37 °C (Figure 2A). We then evaluated the relative stability by measuring changes in their infectivity following prolonged incubation (2, 4, 8, 12, and 24 h) in solutions at physiological temperatures using the focus-forming assay. As expected, beta exhibited the highest thermal stability (Figure 2B), with a half-life approximately twice that of gamma or delta (Figure 2C). These results indicated a correlation between thermal stability and plaque size in all variants except alpha. Interestingly, despite the small plaque size of alpha, its half-life was relatively long, suggesting an alternative mechanism.
Figure 2

Different thermal stability of four SARS-CoV-2 variants. (A) The relative infectivity of each variant after incubation at 4, 24, or 37 °C for 8 h as evaluated via the focus-forming assay. (B) Nonlinear regression of the relative infectivity of each variant following prolonged incubation (2, 4, 8, 12, and 24 h) at physiological temperatures (37 °C). (C) Average half-life values for each variant at 37 °C. All error bars indicate the standard errors of the mean. Mean values for the half-life were compared using one-way ANOVA in GraphPad Prism 8.0 software. Statistical significance was set at p < 0.05 (****, p < 0.0001).

Next, we examined the viral replication rates of these VOCs. Vero E6 cells were infected with VOCs at the same multiplicity of infection (MOI: 0.1). Plaque forming assay and qRT-PCR were then used to assess infectious viral particle numbers and viral RNA concentrations, respectively. Alpha had fewer infectious viral particles than the other variants, although there were no significant differences in viral RNA copy number (Figure 3A,B). Moreover, the intracellular viral RNA concentrations of alpha and gamma were significantly lower than those of the other VOCs (Figure 3C). These results indicate that the viral replication rate of alpha is likely low, contributing to its small plaque size.
Figure 3

Viral replication rate of four SARS-CoV-2 variants. (A) The infectivity of the progeny viruses was evaluated via plaque forming assay completed at 12, 24, and 48 h post infection. (B) Extracellular and (C) intracellular viral RNA were assessed by qRT-PCR with SARS-CoV-2 NP probes. All error bars indicate the standard errors of the mean.

4. Discussion

It is important to analyze these VOCs in terms of both their clinical pathology and virology, as this will help us better understand their increased virulence. For example, plaque size may be associated with contagiousness or viral transmission. Here, we noted that most of our VOCs presented with changes in plaque size. In addition, these changes were largely mirrored by changes in virion stability at physiological temperatures and the concentration of infectious viral particles. Correlation analyses suggested that there is a strong link between plaque size and thermal stability in these VOCs and that the relatively large plaque size of beta may account for its increased thermal resistance. This increased stability may contribute to its pathobiology and transmission, requiring further studies of the viral titer and case fatality rate in humans. Notably, a recent study reported that severity, criticality, and fatality of beta were higher than alpha in COVID-19 patients [12]. Conversely, although alpha presented with increased thermal stability, this did not translate to increased plaque size. This reduced plaque size may be explained by the reduced number of infectious particles produced by alpha under these conditions. Further studies will be required to identify additional determinants of plaque size, including functional mutations, interactions with host factors, and environmental composition. In addition, variants of interest and other variants should also be investigated to effectively control their spread.
  10 in total

1.  Growth, detection, quantification, and inactivation of SARS-CoV-2.

Authors:  James Brett Case; Adam L Bailey; Arthur S Kim; Rita E Chen; Michael S Diamond
Journal:  Virology       Date:  2020-06-13       Impact factor: 3.616

2.  The origin and underlying driving forces of the SARS-CoV-2 outbreak.

Authors:  Shu-Miaw Chaw; Jui-Hung Tai; Shi-Lun Chen; Chia-Hung Hsieh; Sui-Yuan Chang; Shiou-Hwei Yeh; Wei-Shiung Yang; Pei-Jer Chen; Hurng-Yi Wang
Journal:  J Biomed Sci       Date:  2020-06-07       Impact factor: 8.410

3.  Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity.

Authors:  Erik Volz; Verity Hill; John T McCrone; Anna Price; David Jorgensen; Áine O'Toole; Joel Southgate; Robert Johnson; Ben Jackson; Fabricia F Nascimento; Sara M Rey; Samuel M Nicholls; Rachel M Colquhoun; Ana da Silva Filipe; James Shepherd; David J Pascall; Rajiv Shah; Natasha Jesudason; Kathy Li; Ruth Jarrett; Nicole Pacchiarini; Matthew Bull; Lily Geidelberg; Igor Siveroni; Ian Goodfellow; Nicholas J Loman; Oliver G Pybus; David L Robertson; Emma C Thomson; Andrew Rambaut; Thomas R Connor
Journal:  Cell       Date:  2020-11-19       Impact factor: 41.582

Review 4.  The biological and clinical significance of emerging SARS-CoV-2 variants.

Authors:  Kaiming Tao; Philip L Tzou; Janin Nouhin; Ravindra K Gupta; Tulio de Oliveira; Sergei L Kosakovsky Pond; Daniela Fera; Robert W Shafer
Journal:  Nat Rev Genet       Date:  2021-09-17       Impact factor: 53.242

5.  Differential Interactions between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern.

Authors:  Seonghan Kim; Yi Liu; Zewei Lei; Jeffrey Dicker; Yiwei Cao; X Frank Zhang; Wonpil Im
Journal:  J Chem Theory Comput       Date:  2021-12-03       Impact factor: 6.006

6.  Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant.

Authors:  Laith J Abu-Raddad; Hiam Chemaitelly; Houssein H Ayoub; Hadi M Yassine; Fatiha M Benslimane; Hebah A Al Khatib; Patrick Tang; Mohammad R Hasan; Peter Coyle; Sawsan AlMukdad; Zaina Al Kanaani; Einas Al Kuwari; Andrew Jeremijenko; Anvar Hassan Kaleeckal; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Hanan F Abdul Rahim; Gheyath K Nasrallah; Mohamed Ghaith Al Kuwari; Adeel A Butt; Hamad Eid Al Romaihi; Mohamed H Al-Thani; Abdullatif Al Khal; Roberto Bertollini
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

7.  Variant analysis of SARS-CoV-2 genomes.

Authors:  Takahiko Koyama; Daniel Platt; Laxmi Parida
Journal:  Bull World Health Organ       Date:  2020-06-02       Impact factor: 9.408

8.  SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity.

Authors:  Lizhou Zhang; Cody B Jackson; Huihui Mou; Amrita Ojha; Haiyong Peng; Brian D Quinlan; Erumbi S Rangarajan; Andi Pan; Abigail Vanderheiden; Mehul S Suthar; Wenhui Li; Tina Izard; Christoph Rader; Michael Farzan; Hyeryun Choe
Journal:  Nat Commun       Date:  2020-11-26       Impact factor: 14.919

9.  Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.

Authors:  Bette Korber; Will M Fischer; Sandrasegaram Gnanakaran; Hyejin Yoon; James Theiler; Werner Abfalterer; Nick Hengartner; Elena E Giorgi; Tanmoy Bhattacharya; Brian Foley; Kathryn M Hastie; Matthew D Parker; David G Partridge; Cariad M Evans; Timothy M Freeman; Thushan I de Silva; Charlene McDanal; Lautaro G Perez; Haili Tang; Alex Moon-Walker; Sean P Whelan; Celia C LaBranche; Erica O Saphire; David C Montefiori
Journal:  Cell       Date:  2020-07-03       Impact factor: 66.850

10.  Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant.

Authors:  Leonid Yurkovetskiy; Xue Wang; Kristen E Pascal; Christopher Tomkins-Tinch; Thomas P Nyalile; Yetao Wang; Alina Baum; William E Diehl; Ann Dauphin; Claudia Carbone; Kristen Veinotte; Shawn B Egri; Stephen F Schaffner; Jacob E Lemieux; James B Munro; Ashique Rafique; Abhi Barve; Pardis C Sabeti; Christos A Kyratsous; Natalya V Dudkina; Kuang Shen; Jeremy Luban
Journal:  Cell       Date:  2020-09-15       Impact factor: 66.850

  10 in total
  4 in total

1.  Immunodetection assays for the quantification of seasonal common cold coronaviruses OC43, NL63, or 229E infection confirm nirmatrelvir as broad coronavirus inhibitor.

Authors:  Tatjana Weil; Jan Lawrenz; Alina Seidel; Jan Münch; Janis A Müller
Journal:  Antiviral Res       Date:  2022-05-19       Impact factor: 10.103

2.  Analysis of SARS-CoV-2 in Nasopharyngeal Samples from Patients with COVID-19 Illustrates Population Variation and Diverse Phenotypes, Placing the Growth Properties of Variants of Concern in Context with Other Lineages.

Authors:  Tessa Prince; Xiaofeng Dong; Rebekah Penrice-Randal; Nadine Randle; Catherine Hartley; Hannah Goldswain; Benjamin Jones; Malcolm G Semple; J Kenneth Baillie; Peter J M Openshaw; Lance Turtle; Grant L Hughes; Enyia R Anderson; Edward I Patterson; Julian Druce; Gavin Screaton; Miles W Carroll; James P Stewart; Julian A Hiscox
Journal:  mSphere       Date:  2022-05-02       Impact factor: 5.029

Review 3.  Disinfection and decontamination in the context of SARS-CoV-2-specific data.

Authors:  Nevio Cimolai
Journal:  J Med Virol       Date:  2022-07-18       Impact factor: 20.693

4.  Differential effect of SARS-CoV-2 infection on stress granule formation in Vero and Calu-3 cells.

Authors:  Dongbum Kim; Sony Maharjan; Mijeong Kang; Jinsoo Kim; Sangkyu Park; Minyoung Kim; Kyeongbin Baek; Suyeon Kim; Jun Gyo Suh; Younghee Lee; Hyung-Joo Kwon
Journal:  Front Microbiol       Date:  2022-08-23       Impact factor: 6.064

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.